Page 1

November 10 , 2021 im " עו IMV Inc. Announces Third Quarter 2021 Financial and Operational Update DARTMOUTH , Nova Scotia & CAMBRIDGE , Mass .-- ( BUSINESS WIRE ) -- IMV Inc. ( " IMV " or " the Company " ) ( NASDAQ : IMV ; TSX : IMV ) , a clinical - stage company developing immune educating cancer therapies , based on its novel DPX platform , that target solid and blood cancers while preserving patients ' quality of life , today announced its financial and operational results and provided an update for the third quarter ended September 30 , 2021 . " IMV is undergoing a pivotal transformation . We are realigning IMV's strategy to focus on its core competencies in immuno - oncology . We intend to move maveropepimut - S ( MVP - S ) forward on the path to registrational trials and to leverage our versatile DPX platform to further develop a comprehensive portfolio of cancer immunotherapies , both in - house and with partners . As we explore the potential of our DPX delivery platform and the development of new DPX - based candidates , we are actively evaluating potential licensing opportunities for our programs outside of immuno - oncology , " said Andrew Hall , interim Chief Executive Officer of IMV . " Our recent clinical results and translational data are promising and demonstrate the potential of our lead compound in both solid and blood tumors . MVP - S continues to be well tolerated across indications . We have seen sustained response in patients who had already gone through many lines of previous treatments . " Mr. Hall continued . " Additionally , our second immunotherapy candidate , DPX - SurMAGE , has shown encouraging results in preclinical studies and demonstrates the platform's potential to eliver across multiple therapeutic targets . Together , we believe that these results clearly support the expansion of our clinical oncology pipeline across a wider range of tumor antigens and indications both through in - house efforts and an acceleration of business development initiatives . " CLINICAL UPDATE Maveropepimut - S ( MVP - S ) • Phase 2 DeCidE1 Study in Advanced , Recurrent Ovarian Cancer Oliver Dorigo , M.D. , Ph.D. , Director and Associate Professor , Division Gynecologic Oncology , Department of Obstetrics and Gynecology at the Stanford University , CA , is presenting a poster describing translational data from the clinical study in patients with advanced , recurrent ovarian cancer at the Society for Immunotherapy of Cancer ( SITC ) Annual Meeting . Translational analyses showed that : • MVP - S treatment increased survivin - specific T and B cell tumor infiltration , further validating the MVP - S mechanism of action . • Immunogenic / inflamed tumors are more susceptible to treatment with MVP - S .